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ABSTRACT
Melanoma is a recalcitrant disease. The present study used a patient-derived 
orthotopic xenograft (PDOX) model of melanoma to test sensitivity to three molecularly-
targeted drugs and one standard chemotherapeutic. A BRAF-V600E-mutant melanoma 
obtained from the right chest wall of a patient was grown orthotopically in the right 
chest wall of nude mice to establish a PDOX model. Two weeks after implantation, 
50 PDOX nude mice were divided into 5 groups: G1, control without treatment; G2, 
vemurafenib (VEM) (30 mg/kg); G3; temozolomide (TEM) (25 mg/kg); G4, trametinib 
(TRA) (0.3 mg/kg); and G5, cobimetinib (COB) (5 mg/kg). Each drug was administered 
orally, daily for 14 consecutive days. Tumor sizes were measured with calipers twice 
a week. On day 14 from initiation of treatment, TRA, an MEK inhibitor, was the only 
agent of the 4 tested that caused tumor regression (P < 0.001 at day 14). In contrast, 
another MEK inhibitor, COB, could slow but not arrest growth or cause regression of 
the melanoma. First-line therapy TEM could slow but not arrest tumor growth or cause 
regression. The patient in this study had a BRAF-V600E-mutant melanoma and would 
be considered to be a strong candidate for VEM as first-line therapy, since VEM targets 
this mutation. However, VEM was not effective. The PDOX model thus helped identify 
the very-high efficacy of TRA against the melanoma PDOX and is a promising drug for 
this patient. These results demonstrate the powerful precision of the PDOX model for 
cancer therapy, not achievable by genomic analysis alone.
INTRODUCTION
Melanoma is a recalcitrant cancer. When melanoma 
metastasizes to regional lymph nodes, the 5-year survival 
rate is 29% and when it metastasizes to organs, the 
survival rate is 7% [1]. Although recently-developed 
immuno-therapy has extended survival to some extent, the 
5-year survival rates have not been significantly increased 
[2]. Immuno-therapy involving PD-1/PD-L1 blockade has 
had some success with melanoma but is limited by lack 
of sufficient tumor infiltration of activated lymphocytes 
to kill the cancer cells within the tumor in the majority of 
patients tested [3]. Dacarbazine and cisplatinum have been 
used to treat melanoma with limited efficacy [4, 5].
Despite progress in melanoma therapy, there is still 
no cure for stage III and IV disease due to drug resistance, 
tumor heterogeneity and an immunosuppressed tumor 
microenvironment [2]. In addition, the presence of melanin 
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appears to interfere with chemotherapy and radiotherapy 
of this recalcitrant disease [4]. Therefore, more effective 
approaches to melanoma treatment are needed.
Clinically-relevant mouse models of melanoma 
would permit evaluation of tailor-made individualized 
therapy based on the patient-derived tumor. Our laboratory 
pioneered the patient-derived orthotopic xenograft 
(PDOX) nude mouse model with the technique of surgical 
orthotopic implantation (SOI) [6]. Our laboratory has 
developed PDOX model of various types of tumors 
including pancreatic [7–10], breast [11], ovarian [12], 
lung [13], cervical [14], colon [15–17], stomach [18] and 
sarcoma [19–23]. Recent studies from our laboratory have 
demonstrated that PDOX models can be used to develop 
fluorescence-guided surgery [8, 17, 24], novel therapeutics 
such as tumor-targeting bacteria [21, 22, 25] and study the 
tumor microenvironment [26, 27]. The PDOX model, 
developed by our laboratory over the past 28 years, has 
many advantages over subcutaneous-transplant models 
which are growing ectopically under the skin [6]. 
The results of the present study indicate that 
molecular profiling alone may not predict drug response 
and that a PDOX model of the patient’s tumor is necessary 
for precise individualized therapy.
RESULTS AND DISCUSSION
All treatments significantly inhibited tumor growth 
compared to untreated control on day 14 after initiation: 
vemurafenib (VEM): p = 0.0117; temozolomide (TEM), 
p < 0.0001; trametinib (TRA), p < 0.0001; and cobimetinib 
(COB), p < 0.0001. However, tumor regression was 
observed only in the TRA group (Figure 1). 
As shown in Figure 2, TRA regressed tumor 
growth compared to untreated control from day 3 (day 3: 
p = 0.0171; day 7: p < 0.0001; day 10: p < 0.0001; day 14: 
p < 0.0001). On day 14, TRA showed significantly more 
efficacy compared to other therapies evaluated: VEM 
(p < 0.0001), COB (p = 0.0001), and TEM (p = 0.0001). 
The PDOX results suggest that TRA could be used as first-
line therapy for this patient (Figure 2). 
VEM, a tyrosine kinase inhibitor (TKI), targeting 
BRAF-V600E kinase, has been effective in the treatment 
of a BRAF-V600E-mutant melanoma [28–30]. The 
patient in the present study had a BRAF-V600E-mutant 
melanoma and would have been considered to be a strong 
candidate for VEM as first-line therapy. However, not all 
melanomas with mutant BRAF-V600E are responsive 
to VEM [28]. In the present study, VEM efficacy 
was significantly less than TRA (p < 0.0001), TEM 
(p = 0.0090) and COB (p = 0.0239), on day 14 (Figure 2). 
The histology of the original patient tumor and the 
untreated PDOX tumor (Figure 3A, 3B) were similar, 
containing the same types of cells. However, nests of 
cancer cells are seen in the original, but not in the PDOX. 
Also, the original tumor was slightly melanotic, but 
the PDOX tumor did not appear to contain melanin. As 
mentioned above, high levels of melanin in melanoma 
may interfere with therapy [4].
COB is a MEK inhibitor, similar to TRA. It was 
reported that combination therapy of VEM and COB 
improved progression-free survival (PFS) in melanoma 
compared to VEM plus placebo [31]. COB mono-therapy 
was significantly more effective than VEM mono-therapy 
in our study (p = 0.0239). However, TRA was significantly 
more effective than COB (p < 0.0001) as discussed above. 
TEM, an alkylating agent, had been widely used as 
a standard chemotherapy for melanoma. However, after 
approval of molecular-targeting agents, such as VEM, COB, 
and TRA, TEM is not usually the first choice for melanoma. 
Figure 1: Melanoma regression caused by trametinib (TRA) in the PDOX model. (A) The tumor size of the untreated control 
steadily increased. (B) The tumor treated with TRA steadily regressed. Yellow arrows show the PDOX tumor on the right chest wall. Scale 
bar: 20 mm.
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However, not all melanomas have mutations that are 
targeted by these new agents and not all patients with these 
mutations are responsive to these drugs [28]. In our PDOX 
study, TEM was the most effective agent after TRA and 
significantly more effective than VEM (p = 0.0090), despite 
the patient having a BRAF-V600E mutation (Figure 2). 
TRA is a MEK inhibitor, which has been shown to 
act downstream of KRAS, suppressing mitogen-activated 
protein kinase (MAPK) [32]. TRA was shown to affect 
the fibroblast growth factor receptor 1 (FGFR1) leading 
to drug resistance [32]. In a recent study, inhibition of 
FGFR1 in combination with TRA enhanced cancer cell 
death in vitro and in vivo [32]. The results of the present 
report, however, demonstrate that TRA was very active as 
a single agent in a BRAF-V600E mutant melanoma, that 
is only partially inhibited by VEM [30]. 
The results of the present study also demonstrate 
that drug response testing in the PDOX model can 
distinguish efficacy of drugs on individual tumors that 
have similar molecular targets. The results of the present 
study also indicate that molecular profiling alone may not 
predict drug response.
Figure 2: Trametinib (TRA) was the most effective agent against the melanoma PDOX model. Line graph shows relative 
tumor volume at each point relative to the initial tumor volume. TRA significantly regressed the tumor compared to untreated control from 
day 3 to 14. From day 7, TRA was significantly more effective than all other therapies tested. P ≤ 0.0001. Error bars: ± SD. 
Figure 3: Histology of the original patient tumor and the untreated control PDOX tumor. The histology of the PDOX 
untreated tumor closely matched the patient’s tumor with the cells of both looking very similar. (A) Original patient tumor. (B) Untreated 
control PDOX tumor. See Materials and Methods for details. 
Oncotarget71740www.impactjournals.com/oncotarget
The histology of the PDOX untreated tumor closely 
matched the patient’s tumor with the cells of both looking 
very similar (Figure 3), demonstrating the fidelity of the 
PDOX tumor. 
CONCLUSIONS
In the present study, the PDOX model helped 
identify the very high efficacy of TRA against the 
melanoma PDOX. TRA, a targeted MEK inhibitor, was 
the only agent of the 4 tested that caused tumor regression 
and is a promising drug for the patient donor of the 
PDOX. COB is also a targeted MEK inhibitor, but was 
only partially effective against the melanoma PDOX. 
VEM would have been predicted to be active against this 
tumor [30], which has a BRAF- V600E-mutation which 
VEM targets, but VEM was not effective. These results 
demonstrate the powerful precision of the PDOX model, 
not achievable by genomic analysis alone. TRA is a MEK 
inhibitor that also acts synergistically with agents that 
target the fibroblast growth factor receptor (FGFR1) such 
as ponatinib (PON) [32]. Future experiments will test the 
combination of TRA and PON in melanoma and other 
PDOX models. Future experiments will also compare the 
molecular action of TRA and COB to determine why they 
had a strong difference in efficacy in the present case. 
Previously developed concepts and strategies of 
highly selective tumor targeting can take advantage of 
molecular targeting of tumors, including tissue-selective 
therapy which focuses on unique differences between 
normal and tumor tissues [33–38]. 
We recently reported that a PDOX model from 
another melanoma patient responded very well to tomur-
targeting Salmonella typhimurium A1-R [39]. Future 
experiments will test the present and other melanoma 
PDOX with Salmonella typhimurium A1-R.
MATERIALS AND METHODS
Mice 
Athymic nu/nu nude mice (AntiCancer Inc., San 
Diego, CA), 4–6 weeks old, were used in this study. All 
mouse surgical procedures and imaging were performed 
with the animals anesthetized by subcutaneous injection 
of a ketamine mixture (0.02 ml solution of 20 mg/kg 
ketamine, 15.2 mg/kg xylazine, and 0.48 mg/kg 
acepromazine maleate). The response of animals during 
surgery was monitored to ensure adequate depth of 
anesthesia. The animals were observed on a daily basis 
and humanely sacrificed by CO2 inhalation if they met the 
following humane endpoint criteria: severe tumor burden 
(more than 20 mm in diameter), prostration, significant 
body weight loss, difficulty breathing, rotational motion 
and body temperature drop. Animals were housed in a 
barrier facility on a high-efficacy particulate arrestance 
(HEPA)- filtered rack under standard conditions of 
12-hour light/dark cycles. The animals were fed an 
autoclaved laboratory rodent diet. All animal studies 
were conducted in accordance with the principles and 
procedures outlined in the National Institutes of Health 
Guide for the Care and Use of Animals under Assurance 
Number A3873-1. 
Patient-derived tumor 
A 75-year-old female patient was diagnosed with a 
melanoma of the right chest wall. The tumor was resected 
in the Department of Surgery, University of California, 
Los Angeles (UCLA). Written informed consent was 
provided by the patient, and the Institutional Review 
Board (IRB) of UCLA approved this experiment. 
Establishment of PDOX models of melanoma by 
surgical orthotopic implantation (SOI)
 A fresh sample of the melanoma of the patient was 
obtained and transported immediately to the laboratory 
at AntiCancer, Inc., on wet ice. The sample was cut into 
5-mm fragments and implanted subcutaneously in nude 
mice. After three weeks, the subcutaneously-implanted 
tumors grew to more than 10 mm in diameter. The 
subcutaneously-grown tumors were then harvested and 
cut into small fragments (3 mm3). After nude mice were 
anesthetized with the ketamine solution described above, 
a 5-mm skin incision was made on the right chest into 
the chest wall, which was split to make space for the 
melanoma tissue fragment. A single tumor fragment was 
implanted orthotopically into the space to establish the 
PDOX model. The wound was closed with a 6–0 nylon 
suture (Ethilon, Ethicon, Inc., NJ, USA) [23, 24]. 
Treatment study design in the PDOX model of 
melanoma 
PDOX mouse models were randomized into five 
groups of 10 mice each: G1, untreated control (n = 10); 
G2, treated with VEM (30 mg/kg, n = 10); G3, TEM 
(25 mg/kg, n = 10); G4, TRA (0.3 mg/kg, n = 10); G5, 
COB (5 mg/kg, n = 10) [1]. Each drug was administrated 
orally daily for 14 consecutive days. Tumor length and 
width were measured twice a week. Tumor volume was 
calculated with the following formula: Tumor volume 
(mm3) = length (mm) × width (mm) × width (mm) × 1/2. 
Data are presented as mean ± SD. The tumor volume ratio 
is defined at the tumor volume at any given time point 
relative to the initial tumor volume. 
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Tumor histology 
Tumor tissue was removed along with surrounding 
normal tissues at the time of resection from the patient 
and untreated control PDOX. The tissues were fixed in 
10% formalin and embedded in paraffin before sectioning 
and staining. Tissue sections (3 μm) were deparaffinized 
in xylene and rehydrated in an ethanol series. Hematoxylin 
and eosin (H&E) staining was performed according 
to standard protocols. Histological examination was 
performed with a BHS system microscope. Images were 
acquired with INFINITY ANALYZE software (Lumenera 
Corporation, Ottawa, Canada). 
Statistical analysis 
JMP version 11.0 was used for all statistical 
analyses. Significant differences for continuous variables 
were determined using the Mann-Whitney U test. Line 
graphs expressed average values and error bar showed SD. 
A probability value of P ≤ 0.05 was considered statistically 
significant. 
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